**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1-10. (Cancelled)

11. (Currently amended) A compound of formula (IIB)



(IIB)

or a salt ~~or prodrug~~ thereof

where

X is O, or S, S(O) or $S(O)_2$, NH or $NR^8$ where $R^8$ is hydrogen or $C_{1-6}$alkyl,

Z is O or S,

n is an integer of from 1 to 6 and $R^9$ is hydrogen,

or n is 0 or an integer of from 1 to 6 and $R^9$ is ethenyl, optionally substituted phenyl, optionally substituted pyridyl or optionally substituted furanyl where optional substituents for $R^9$ groups are $C_{1-3}$alkoxy, $C_{1-3}$alkyl, halo or nitro,

$R^6$ and $R^7$ are independently selected from hydrogen, halo, $C_{1-4}$alkyl, $C_{1-4}$alkoxy, $C_{1-4}$alkoxymethyl, di($C_{1-4}$alkoxy)methyl, $C_{1-4}$alkanoyl, trifluoromethyl, cyano, amino, $C_{2-5}$alkenyl, $C_{2-5}$alkynyl, a phenyl group, a benzyl group or a 5-6-membered heterocyclic group with 1-3 heteroatoms, selected independently from O, S and N, which heterocyclic group may be aromatic or non-aromatic and may be saturated and linked via a ring carbon or nitrogen atom or unsaturated and linked via a ring carbon atom, and which phenyl, benzyl or heterocyclic group may bear on one or more ring carbon atoms up to 5 substituents selected from hydroxy, halogeno, $C_{1-3}$alkyl, $C_{1-3}$alkoxy, $C_{1-3}$alkanoyloxy, trifluoromethyl, cyano, amino, nitro, $C_{2-4}$alkanoyl, $C_{1-4}$alkanoylamino, $C_{1-4}$alkoxycarbonyl, $C_{1-4}$alkylsulphanyl, $C_{1-4}$alkylsulphinyl,

$C_{1-4}$alkylsulphonyl, carbamoyl, N-$C_{1-4}$alkylcarbamoyl, N,N-di($C_{1-4}$alkyl)carbamoyl, aminosulphonyl, N-$C_{1-4}$alkylaminosulphonyl, N,N-di($C_{1-4}$alkyl)aminosulphonyl, $C_{1-4}$alkylsulphonylamino, and a saturated heterocyclic group selected from morpholino, thiomorpholino, pyrrolidinyl, piperazinyl, piperidinyl, imidazolidinyl and pyrazolidinyl, which saturated heterocyclic group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno, $C_{1-3}$alkyl, $C_{1-3}$alkoxy, $C_{1-3}$alkanoyloxy, trifluoromethyl, cyano, amino, nitro and $C_{1-4}$alkoxycarbonyl, $R^1$ is hydrogen, $R^4$ is hydrogen, halo, $C_{1-4}$alkyl or $C_{1-4}$alkoxy ~~and n is 0, or an integer of from 1 to 6~~,

$R^{66}$ is halo, cyano, nitro, trifluoromethyl, $C_{1-3}$alkyl, $-NR^{12}R^{13}$ [(]]wherein $R^{12}$ and $R^{13}$, which may be the same or different, each represents hydrogen or $C_{1-3}$alkyl, or a group $-X^1R^{14}$ wherein $X^1$ represents a direct bond, -O-, $-CH_2-$, -OC(O)-, -C(O)-, -S-, -SO-, $-SO_2-$, $-NR^{15}C(O)-$, $-C(O)NR^{16}-$, $-SO_2NR^{17}-$, $-NR^{18}SO_2-$ or $-NR^{19}-$ wherein $R^{15}$, $R^{16}$, $R^{17}$, $R^{18}$ and $R^{19}$ each independently represents hydrogen, $C_{1-3}$alkyl or $C_{1-3}$alkoxy$C_{2-3}$alkyl, and $R^{14}$ is hydrogen or $C_{1-5}$alkyl which may be unsubstituted or which may be substituted with one or more groups selected from hydroxy, oxiranyl, fluoro, chloro, bromo and amino including $C_{1-3}$alkyl and trifluoromethyl; or $-R^9R^{38}$ and wherein $R^{38}$ represents a pyridone group, a phenyl group or a 5-6-membered aromatic heterocyclic group linked via carbon or nitrogen with 1-3 heteroatoms selected from O, N and S, which pyridone, phenyl or aromatic heterocyclic group may carry up to 5 substituents selected from hydroxy, nitro, halogeno, amino, $C_{1-4}$alkyl, $C_{1-4}$alkoxy, $C_{1-4}$hydroxyalkyl, $C_{1-4}$aminoalkyl, $C_{1-4}$alkylamino, $C_{1-4}$hydroxyalkoxy, oxo, cyano$C_{1-4}$alkyl, cyclopropyl, $C_{1-4}$alkylsulphonyl$C_{1-4}$alkyl, $C_{1-4}$alkoxycarbonyl, di($C_{1-4}$alkyl)amino, $C_{1-4}$alkylamino$C_{1-4}$alkyl, $C_{1-4}$alkanoyl, di($C_{1-4}$alkyl)amino$C_{1-4}$alkyl, $C_{1-4}$alkylamino$C_{1-4}$alkoxy, di($C_{1-4}$alkyl)amino$C_{1-4}$alkoxy, carboxy, carboxamido, trifluoromethyl, cyano, $-C(O)NR^{39}R^{40}$, $-NR^{41}C(O)R^{42}$ wherein $R^{39}$, $R^{40}$, $R^{41}$ and $R^{42}$, which may be the same or different, each represents hydrogen, $C_{1-4}$alkyl, hydroxy$C_{1-4}$alkyl or $C_{1-3}$alkoxy$C_{2-3}$alkyl and a group $-(-O-)_f(C_{1-4}alkyl)_g$ringD wherein f is 0 or 1, g is 0 or 1 and ring D is a cyclic group selected from $C_{3-6}$cycloalkyl, aryl or 5-6-membered saturated or unsaturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which cyclic group may bear one or more substituents selected from halo and $C_{1-4}$alkyl; and wherein $R^9$ is a $C_{1-8}$alkylene group optionally substituted by one or more substituents selected from hydroxy, halogeno and amino ;

and $R^{67}$ is $C_{1-6}$alkoxy substituted with a group $X^1R^{38}$ wherein $X^1$ and $R^{38}$ are as defined above or $R^{67}$ is 3-morpholinopropoxy.

12. (Previously presented) A method of preparing a compound according to claim 11, which comprises reacting a compound of formula (VII)



(VII)

where $R^{1'}$, $R^{2'}$, $R^{3'}$, and $R^{4'}$ are respectively equivalent to a group $R^1$, $R^{68}$, $R^{67}$ and $R^4$ as defined in claim 11 or a precursor thereof, and $R^{85}$ is a leaving group, with a compound of formula (VIII)

$$H\text{-}X\text{-}R^{8''}$$

(VIII)

where X, is as defined in claim 11, and $R^{8''}$ is



where Z, n, $R^6$, $R^7$ and $R^9$ are as defined in claim 11.

13-14. (Canceled)

15. (Currently amended) A pharmaceutical composition comprising a compound of formula (IIB) as defined in claim 11, or a salt ~~or prodrug~~ thereof, in combination with a pharmaceutically acceptable carrier.

16. (Currently amended) A compound according to claim 11 or a salt ~~or prodrug~~ thereof wherein $R^1$ and $R^4$ are both hydrogen.

17. (Previously presented) A compound according to claim 11 wherein $R^{67}$ is 3-morpholinopropoxy.

18. (Previously presented) A compound according to claim 11 wherein $R^6$ and $R^7$ are independently selected from hydrogen, halo, $C_{1-4}$alkoxy, cyano, trifluoromethyl or phenyl.

19. (Previously presented) A compound according to claim 11 wherein $R^6$ and $R^7$ are both hydrogen.

20. (Cancelled)

21. (Currently amended) A method of treating colorectal or breast cancer in a warm blooded animal comprising administering to said animal an effective amount of a compound according to claim 11 or a salt ~~or prodrug~~ thereof.